Exenatide - a physiological option for a pathological disease
17 Sep 2009, 1504 Hrs

Add comment          Mail          Print          Write to Editor

* Education Directory * Exam Results * Who is Who * Information *Tutorials * Articles * Quote * Classified

New Delhi, Sep.17 The treatment of Type 2 diabetic patients, especially those who are obese, is full of challenges.

According to Dr. Vikas Ahluwalia, President of the Diabetes Care Foundation of India, apart from blood sugar levels, there are several other treatment end points and issues that need to be addressed in such patients.

He says that the basic pathophysiology of type 2 diabetes includes three main defects, namely insulin deficiency, excess glucose output and insulin resistance.

Despite the advances in the management of diabetes and development of newer better insulins, there are various unsolved problems in the treatment of obese type 2 diabetic patients as in:

1. HbA1c targets are achieved only in a minority of patients.

2. Increase in body weight by most anti-diabetic drugs (insulin, sulfonylureas, glitazones)

3. Weight gain is associated with an increase in blood pressure, LDL, and chronic inflammation as well as decrease in HDL.

4. Risk of severe hypoglycemia is high in type 2 diabetic with long standing disease.

5. Continuous progression of diabetes deterioration caused by beta cell loss.

Recently increased evidence from multiple randomized control studies have shown that drugs mimicking the physiological incretin effect on insulin secretion provide better and effective blood sugar control in obese diabetics, Dr Ahluwalia says.

Incretin hormone secretion and actions are impaired in type 2 diabetes. Also beta cell responsiveness to GLP - 1 is reduiced, but exogenous GLP - 1 can still restore beta cell sensitivity to glucose and improve glucose induced insulin secretion.

One such drug called Exenatide (Byetta), which is a synthetic version of salivary protein found in the gila monster, binds to human GLP - 1 receptors on beta cells in vitro. Such incretin based therapies of type 2 diabetes may be expected to reduce hyperglycemia and HbA1c levels, improve alpha cell and beta cell function, improve insulin sensitivity and improve metabolism.

Exenatide is not beneficial for every type 2 duabetic patient. Patient selection is very important before starting exanatide. It is primarily indicated in the following situations:

1. BMI > 30

2. HbA1c > 8.5 on 2/3 antidiabetic drugs

3. not willing for SMBG

4. always feels hungary

5. wants to lose weight

6. anxious about hypoglycemia with insulin.

As with insulin, Exenatide has to be injected subcutaneously once or twice daily. Main side effects include nausea, diarrhea and pancreatitis (0.3 cases in 1000 patients). By Dr. Vikas Ahluwalia(ANI)

Related Latest

New discovery could make plants disease resistant and high-yielding Sleep apnea ups heart disease risk in kidney transplant patients Heart disease found in 3,000 year old Egyptian mummies Obesity epidemic negating efforts to cut heart disease risks Molecular trigger that helps prevent aging and disease found Heavy drinking 'cuts men's heart disease risk' Egyptian mummies show heart disease had ancient origin Night shift, overtime, shortened sleep 'can raise heart disease risk' Smoking may increase Lou Gehrig's disease risk Marker of oxidative stress may help predict heart disease risk

Related Latest

As far as Kashmir issue is concerned, India will not redraw borders: Singh Pakistan has not done enough on the Mumbai terror attacks: Manmohan Singh No apprehension about US viewing India differently: Manmohan Singh Winters leave Ladakh out of bound, make stocking of food material a must Eco-friendly vehicles rally held in Delhi People worship Highway Goddess for safe journey in Chennai Lucknow Zoo authorities treating tiger for cancer Hussey ready to cop criticism, but will let bat do the talking PAC supports idea of making Pak Army's financial records public Pak heading towards 'demographic disaster', warn experts

• Pakistan has not done enough on the Mumbai terror attacks: Manmohan Singh
• As far as Kashmir issue is concerned, India will not redraw borders: Singh
• No apprehension about US viewing India differently: Manmohan Singh
• Winters leave Ladakh out of bound, make stocking of food material a must
• Eco-friendly vehicles rally held in Delhi

• भारतीय क्रिकेट की मजबूत दीवार
• कंगारूओं के आगे ढेर, चीतों से कैसे मुकाबला करेंगें शेर
• Reducing greenhouse gases may not be enough to slow global warming
• बीकानेर महापौर चुनावः एक विश्लेषण
• Deepawali: The Festival Of Lights